Periprosthetic osteolysis: Characterizing the innate immune response to titanium wear-particles

Journal of Orthopaedic Research

Volumn 28, Issue 11, 2010, Pages 1418-1424

  St Pierre, Christine A ^a   Chan, Melvin ^a   Iwakura, Yoichiro ^b,c   Ayers, David C ^a   Kurt Jones, Evelyn A ^a   Finberg, Robert W ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

IL 1; Inflammasome; NALP3; Neutrophils; Titanium

Indexed keywords

CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; INTERLEUKIN 1; TITANIUM;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; HIP ARTHROPLASTY; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MACROPHAGE; METABOLISM; MOUSE; NEUTROPHIL CHEMOTAXIS; OSTEOLYSIS; PHYSIOLOGY;

ANIMALS; ARTHROPLASTY, REPLACEMENT, HIP; CARRIER PROTEINS; CELLS, CULTURED; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1; MACROPHAGES; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; OSTEOLYSIS; TITANIUM;

EID: 77957957053     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21149     Document Type: Article

References (39)

1. Ingham E, Fisher J. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26:1271-1286.
2. Jacobs JJ, Roebuck KA, Archibeck M, et al. 2001. Osteolysis: basic science. Clin Orthop Relat Res 393:71-77.
3. Saeed S, Revell PA. 2001. Production and distribution of interleukin 15 and its receptors (IL-15Ralpha and ILR2beta) in the implant interface tissues obtained during revision of failed total joint replacement. Int J Exp Pathol 82:201-209.
4. Revell PA. 2008. The combined role of wear particles, macrophages and lymphocytes in the loosening of total joint prostheses. J R Soc Interface 5:1263-1278.
5. Stea S, Visentin M, Granchi D, et al. 2000. Cytokines and osteolysis around total hip prostheses. Cytokine 12:1575-1579.
6. Granchi D, Verri E, Ciapetti G, et al. 1998. Bone-resorbing cytokines in serum of patients with aseptic loosening of hip prostheses. J Bone Joint Surg Br 80:912-917.
7. Rader CP, Sterner T, Jakob F, et al. 1999. Cytokine response of human macrophage-like cells after contact with polyethylene and pure titanium particles. J Arthroplasty 14:840-848.
8. Boynton EL, Waddell J, Meek E, et al. 2000. The effect of polyethylene particle chemistry on human monocytemacrophage function in vitro. J Biomed Mater Res 52:239-245.
9. Epstein NJ, Warme BA, Spanogle J, et al. 2005. Interleukin-1 modulates periprosthetic tissue formation in an intramedullary model of particle-induced inflammation. J Orthop Res 23:501-510.
10. Stashenko P, Dewhirst FE, Peros WJ, et al. 1987. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 138:1464-1468.
11. Assuma R, Oates T, Cochran D, et al. 1998. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 160:403-409.
12. Thomson BM, Mundy GR, Chambers TJ. 1987. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 138:775-779.
13. Hornung V, Bauernfeind F, Halle A, et al. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847-856.
14. Martinon F, Petrilli V, Mayor A, et al. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-241.
15. Dostert C, Petrilli V, Van Bruggen R, et al. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320:674-677.
16. Masumoto J, Taniguchi S, Ayukawa K, et al. 1999. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chem 274:33835-33838.
17. Mariathasan S, Newton K, Monack DM, et al. 2004. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430:213-218.
18. Mariathasan S, Monack DM. 2007. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7:31-40.
19. Martinon F, Tschopp J. 2005. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 26:447-454.
20. Agostini L, Martinon F, Burns K, et al. 2004. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20:319-325.
21. Chen CJ, Shi Y, Hearn A, et al. 2006. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 116:2262-2271.
22. Hayat MA. 1978. Introduction: to biological scanning electron microscopy. Baltimore: University Park Press; xviii, 323 p.
23. Nagai Y, Akashi S, Nagafuku M, et al. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3:667-672.
24. Wright SD, Ramos RA, Tobias PS, et al. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433.
25. Chen CJ, Kono H, GolenbockD, et al. 2007. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13:851-856.
26. Lee JM, Salvati EA, Betts F, et al. 1992. Size of metallic and polyethylene debris particles in failed cemented total hip replacements. J Bone Joint Surg Br 74:380-384.
27. Halle A, Hornung V, Petzold GC, et al. 2008. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857-865.
28. Muruve DA, Petrilli V, Zaiss AK, et al. 2008. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452:103-107.
29. Chiba J, Rubash HE, Kim KJ, et al. 1994. The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop Relat Res 300:304-312.
30. Schwarz EM, Lu AP, Goater JJ, et al. 2000. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis. J Orthop Res 18:472-480.
31. Schumacher HR, Agudelo CA. 1972. Intravascular degranulation of neutrophils: an important factor in inflammation? Science 175:1139-1140.
32. Abramson SB, Amin A. 2002. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 41:972-980.
33. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196-2204.
34. Jiang Y, Genant HK, Watt I, et al. 2000. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43:1001-1009.
35. Sud S, Yang SY, Evans CH, et al. 2001. Effects of cytokine gene therapy on particulate-induced inflammation in the murine air pouch. Inflammation 25:361-372.
36. Kimble RB, Vannice JL, Bloedow DC, et al. 1994. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 93:1959-1967.
37. Baltzer AW, Whalen JD, Wooley P, et al. 2001. Gene therapy for osteoporosis: evaluation in a murine ovariectomy model. Gene Ther 8:1770-1776.
38. Gordon A, Kiss-Toth E, Stockley I, et al. 2008. Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. Arthritis Rheum 58:3157-3165.
39. Caicedo MS, Desai R, McAllister K, et al. 2008. Soluble and particulate Co-Cr-Mo alloy implant metals activate the inflammasome danger signaling pathway in human macrophages: a novel mechanism for implant debris reactivity. J Orthop Res 27:847-854.